2 results
Approved WMOCompleted
Primary ObjectiveThe primary objective of this study is to evaluate the effect of 12 weeks of treatment with 2 different doses of oral AQX-1125 (100 mg or 200 mg) administered once daily compared to placebo on the change from Baseline (Visit 2) to…
Approved WMORecruiting
In this study we want to evaluate the safety and efficacy of the new drug ZPL389. ZPL389 is tested in various strengths in patients with moderate or severe atopic dermatitis. The effects of ZPL389 are compared with those of a placebo.